HBPCFHelix Biopharma Corp.

About Helix Biopharma Corp. (HBPCF)

Helix Biopharma Corp. (HBPCF) is a Biotechnology company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the Pink tier.

Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.

HBPCF key facts

Ticker symbol

HBPCF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

1995

Employees

28

Estimated market cap

$31.28M (as of May 12, 2025)

Shares outstanding

53,021,536

Reporting standard

International Reporting: Toronto Stock Exchange

Audit status

Audited

Fiscal year end

7/31

Helix Biopharma Corp. leadership

• Jacek Antas — CEO
• Hatem Kawar — CFO
• Frank Gary Renshaw — CMO
• Srikanth Sola — CSO
• Nancy Glaister — Securities Counsel
• Christof Boehler — Business Development

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with H